BioDuro and Silicogenix collaborate to advance non-traditional drug development
Ella Day | June 11, 2025 | News story | Manufacturing Services, Manufacturing and Production, Research and Development | BioDuro, Oncology, Pharmacy, Silicogenix, contract research, contract research development and manufacturing organisation (CRDMO), drug development
BioDuro, a contract research, development and manufacturing organisation, has announced a strategic partnership with small molecule design specialist Silicogenix (SGX) to accelerate polypharmacology and non-traditional drug development. The collaboration will combine BioDuro’s drug discovery capabilities with SGX’s design frameworks to streamline the development of complex therapeutics.
Headquartered in California, US, BioDuro provides services spanning early discovery to commercial manufacturing across the pharma sector, including pharmacokinetics, drug metabolism and drug substance manufacturing. The company operates across seven sites in the US and China.
“We are excited to partner with SGX to enable an alternative path for new drug discovery, propelling therapeutics with the potential to save lives,” said Subas Sakya, chief scientific officer at BioDuro.
SGX develops small molecule design technology to support polypharmacology and non-traditional approaches for conditions such as cancer and complex diseases. Its platform enables access to a broad section of the human proteome, assisting biopharma companies to design and test therapies with greater speed and cost-efficiency compared to conventional methods.
“We believe our collective approach will help biopharmaceutical companies greatly expedite the development cycle for therapeutics that address unmet medical needs,” said Shailesh Date, co-founder of SGX.
The partnership aims to support the discovery of innovative medicines and enable more efficient development of therapies addressing underserved indications.
Ella Day
11/6/25
Related Content
Symeres announces acquisition of DGr Pharma
Symeres, a Contract Research, Development and Manufacturing Organization (CRDMO) has acquired DGr Pharma, a drug …
BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …
BioDuro and Atombeat partner to accelerate AI-powered peptide drug discovery
BioDuro and Atombeat have announced a partnership to launch an artificial intelligence (AI)-driven platform designed …
